Profile data is unavailable for this security.
About the company
Euroapi SAS is a France-based company. The Company is engaged in the development, manufacture and supply of active-ingredient solutions to its healthcare partners. It offers vitamin B12, prostaglandins, oligonucleotides, peptides, corticoids and hormones, anti-infectives, opiates (morphine, codeine, thebaine, etc.), analgesics, etc. The Company also provides technologies and develops molecules through it’s Contract Development and Manufacturing Organization (CDMO). It’s CDMO services include Tides, Prostaglandins, Particle Engineering, Microbial Fermentation, Small Molecules Synthesis, Steroids and Hormones and Opiates & Controlled Substances. It has production sites located in France, the United Kingdom, Germany, Italy and Hungary.
- Revenue in EUR (TTM)1.02bn
- Net income in EUR-189.70m
- Incorporated2020
- Employees3.67k
- LocationEuroapi SA15, rue TraversierePARIS 75012FranceFRA
- Phone+33 189206200
- Websitehttps://www.euroapi.com/en
More ▼
Mergers & acquisitions
| Acquired company | EAPI:PAR since announced | Transaction value |
|---|---|---|
| BianoGMP GmbH | -78.20% | 10.82m |
Data delayed at least 15 minutes, as of Apr 19 2024 14:29 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Transgene SA | 7.63m | -22.33m | 146.84m | 158.00 | -- | 9.38 | -- | 19.24 | -0.2227 | -0.2227 | 0.0759 | 0.1553 | 0.1368 | -- | 4.28 | 48,316.46 | -40.00 | -24.81 | -50.27 | -29.79 | -- | -- | -292.48 | -193.24 | -- | -- | 0.4764 | -- | -23.68 | 1.51 | 31.94 | -- | 14.44 | -- |
| Eurobio Scientific SA | 128.01m | 7.91m | 152.09m | 304.00 | 19.65 | 0.9605 | 6.24 | 1.19 | 0.7552 | 0.7552 | 11.91 | 15.45 | 0.4856 | 3.75 | 4.48 | 948,222.30 | 3.00 | 21.70 | 3.53 | 28.79 | 45.28 | 50.59 | 6.18 | 25.06 | 2.70 | 4.11 | 0.3799 | 0.00 | -17.38 | 29.03 | -58.81 | -- | -6.24 | -- |
| Genfit SA | 38.18m | -28.89m | 158.72m | 159.00 | -- | 2.34 | -- | 4.16 | -0.5814 | -0.5814 | 0.7681 | 1.36 | 0.1961 | 542.00 | 3.52 | 240,100.60 | -14.84 | -12.57 | -18.55 | -15.30 | 94.32 | 94.96 | -75.69 | -76.23 | 2.94 | -7.78 | 0.5080 | -- | 43.70 | 38.49 | -21.82 | -- | -3.27 | -- |
| Inventiva SA | 17.48m | -110.43m | 165.83m | 112.00 | -- | -- | -- | 9.49 | -2.45 | -2.45 | 0.3854 | -0.6146 | 0.1884 | -- | 9.18 | 156,044.60 | -116.84 | -54.30 | -207.08 | -69.98 | -- | -- | -620.31 | -669.97 | 0.9524 | -19.98 | 6.96 | -- | 43.50 | 40.46 | -103.46 | -- | -0.33 | -- |
| Cellectis SA | 22.94m | -55.71m | 170.14m | -- | -- | 1.84 | -- | 7.42 | -1.06 | -1.56 | 0.445 | 1.29 | 0.0998 | -- | 40.86 | -- | -27.15 | -21.38 | -34.66 | -26.37 | -- | -61.60 | -272.10 | -268.89 | -- | -4.96 | 0.5559 | -- | -33.35 | -5.27 | -5.77 | -- | -14.21 | -- |
| Aelis Farma SA | 5.55m | -5.57m | 172.35m | 22.00 | -- | 10.02 | -- | 31.04 | -0.4123 | -0.4123 | 0.4187 | 1.30 | 0.1405 | -- | 1.36 | 252,409.10 | -14.09 | -30.28 | -22.24 | -49.56 | -- | -- | -100.29 | -168.22 | 2.41 | -- | 0.1337 | -- | -58.03 | -- | -2,589.20 | -- | -- | -- |
| Innate Pharma SA | 51.90m | -7.57m | 173.85m | 179.00 | -- | 3.35 | -- | 3.35 | -0.0939 | -0.0939 | 0.6451 | 0.642 | 0.2648 | -- | 5.67 | 289,949.70 | -3.86 | -8.83 | -4.87 | -12.11 | 94.50 | 93.17 | -14.59 | -55.55 | -- | -- | 0.6408 | -- | 4.68 | -8.27 | 86.94 | -- | 10.50 | -- |
| Sensorion SA | 0.00 | -22.06m | 219.78m | 50.00 | -- | 4.12 | -- | -- | -0.2063 | -0.2063 | 0.00 | 0.1779 | 0.00 | -- | -- | -- | -51.64 | -35.12 | -71.66 | -46.97 | -- | -- | -- | -- | -- | -- | 0.0794 | -- | -- | -- | 4.94 | -- | 126.45 | -- |
| Nanobiotix SA | 0.00 | -58.78m | 244.86m | 101.00 | -- | -- | -- | -- | -1.68 | -1.68 | 0.00 | -1.53 | 0.00 | -- | -- | 0.00 | -97.14 | -55.16 | -411.11 | -75.16 | -- | -- | -- | -89,710.66 | -- | -6.62 | -- | -- | -100.00 | -- | -21.36 | -- | -42.16 | -- |
| Euroapi SA | 1.02bn | -189.70m | 246.00m | 3.67k | -- | 0.2646 | -- | 0.2414 | -2.01 | -2.01 | 10.73 | 9.78 | 0.6086 | 1.38 | 4.24 | 277,705.10 | -11.34 | -- | -15.93 | -- | 16.15 | -- | -18.63 | -- | 0.6573 | -- | 0.1955 | -- | 3.87 | -- | -1,164.67 | -- | -- | -- |
| Carbios SA | -100.00bn | -100.00bn | 313.33m | 104.00 | -- | 1.34 | -- | -- | -- | -- | -- | 13.92 | -- | -- | -- | -- | -- | -9.92 | -- | -10.77 | -- | -- | -- | -3,365.22 | 9.43 | -- | 0.1719 | -- | -65.71 | -53.32 | 1.86 | -- | -- | -- |
| Medincell SA | 10.85m | -26.42m | 316.87m | 138.00 | -- | -- | -- | 29.21 | -1.02 | -1.02 | 0.4086 | -0.8965 | 0.2605 | -- | 6.81 | 75,853.15 | -63.46 | -59.54 | -115.15 | -117.36 | 60.43 | 68.38 | -243.58 | -451.26 | -- | -4.29 | 1.69 | -- | 141.78 | 8.96 | -29.04 | -- | -2.87 | -- |
Data as of Apr 19 2024. Currency figures normalised to Euroapi SA's reporting currency: Euro EUR
22.91%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Kopernik Global Investors LLCas of 12 Mar 2024 | 4.98m | 5.24% |
| MAK Capital One LLCas of 08 Feb 2024 | 4.77m | 5.01% |
| CDC Croissance SAas of 26 Jan 2024 | 4.75m | 4.99% |
| The Vanguard Group, Inc.as of 05 Apr 2024 | 1.78m | 1.87% |
| Brandes Investment Partners LPas of 10 Apr 2024 | 1.35m | 1.42% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 1.03m | 1.08% |
| Mirova SA (Investment Management)as of 31 Jan 2024 | 958.76k | 1.01% |
| Cr�dit Mutuel Asset Management SAas of 29 Sep 2023 | 860.93k | 0.91% |
| BlackRock Fund Advisorsas of 04 Apr 2024 | 654.27k | 0.69% |
| Edmond de Rothschild Asset Management (France) SAas of 29 Sep 2023 | 652.31k | 0.69% |
More ▼
Data from 31 Dec 2023 - 28 Mar 2024Source: FactSet Research Systems Inc.
